On the enchancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin

Microbiology

Volumn 152, Issue 7, 2006, Pages 1891-1895

  Atassi, M Zouhair ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BUFFER; EPITOPE; FORMALDEHYDE; HEMAGGLUTININ; HUMAN SERUM ALBUMIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; SODIUM DIHYDROGEN PHOSPHATE; 16S TOXIN, CLOSTRIDIUM BOTULINUM; BACTERIAL TOXIN; IMMUNOLOGICAL ADJUVANT;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; CELLULAR IMMUNITY; CLOSTRIDIUM BOTULINUM; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG RESEARCH; DYSTONIA; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MUSCLE SPASM; NONHUMAN; NOTE; PRIORITY JOURNAL; RABBIT; TREATMENT DURATION; ANIMAL; BLOOD; CHEMISTRY; CLOSTRIDIUM BOTULINUM TYPE B; IMMUNOLOGY;

CLOSTRIDIUM BOTULINUM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; CLOSTRIDIUM BOTULINUM TYPE B; FORMALDEHYDE; HEMAGGLUTININS; HUMANS; IMMUNIZATION; MICE;

EID: 33746092491     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/mic.0.28862-0     Document Type: Note

References (38)

1. Aoki, K. R. (2002). Immunologic and other properties of therapeutic botulinum toxin serotypes. In Scientific and Therapeutic Aspects of Botulinum Toxin, pp. 103-113. Edited by M. F. Brin, M. Hallett & J. Jankovic. Philadelphia: Lippincott Williams & Wilkins.
2. Arimitsu, H., Inoue, K., Sakaguchi, Y., Lee, J., Fujinaga, Y., Watanabe, T., Ohyama, T., Hirst, R. & Oguma, K. (2003). Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia. Infect Immun 71, 1599-1603.
3. Atassi, M. Z. (1977). Chemical modification and cleavage of proteins and chemical strategy in immunochemical studies of proteins. In Immunochemistry of Proteins, vol. 1, pp. 1-161. Edited by M. Z. Atassi. New York: Plenum.
4. Atassi, M. Z. (1984). Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur J Biochem 145, 1-20.
5. Atassi, M. Z. (2002). Immune recognition and cross-reactivity of botulinum neurotoxins. In Scientific and Therapeutic Aspects of Botulinum Toxins, pp. 385-408. Edited by M. F. Brin, M. Hallett & J. Jankovic. Philadelphia: Lippincott Williams & Wilkins.
6. Atassi, M. Z. (2004). Basic immunological aspects of botulinum toxin therapy. Mov Disord Suppl 8, S68-S84.
7. Atassi, M. Z. & Oshima, M. (1999). Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 19, 219-260.
8. Atassi, M. Z., Dolimbek, B. Z., Hayakari, M., Middlebrook, J. L., Whitney, B. & Oshima, M. (1996). Mapping of the antibody-binding regions on botulinum neurotoxin H-Chain domain 855-1296 with anti-toxin antibodies from three host species. J Protein Chem 15, 691-700.
9. Atassi, M. Z., Dolimbek, G. S., Deitiker, P. R., Aoki, K. R. & Dolimbek, B. Z. (2005). Submolecular recognition profiles in two mouse strains of non-protective and protective anti-bodies against botulinum neurotoxin A. Mol Immunol 42, 1509-1520.
10. Borodic, G. E., Acquadro, M. & Johnson, E. A. (2001). Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 10, 1531-1544.
11. Brashear, A., Lew, M. F., Dykstra, D. D. & 10 other authors (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53, 1439-1446.
12. Brashear, A., McAfee, A. L., Kuhn, E. R. & Fyffe, J. (2004). Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 85, 705-709.
13. Callaway, J. E., Arezzo, J. C. & Grethlein, A. J. (2002). Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Dis Mon 48, 367-383.
14. Chen, J., Fitos, I. & Hage, D. S. (2006). Chromatographic analysis of allosteric effects between ibuprofen and benzodiazepines on human serum albumin. Chirality 18, 24-36.
15. Coyle, E. M., Blazer, L. L., White, A. A., Hess, J. L. & Boyle, M. D. (2006). Practical applications of high-affinity, albumin-binding proteins from a group G streptococcal isolate. Appl Microbiol Biotechnol 71, 39-45.
16. N domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest 34, 119-142.
17. Dressler, D. & Bigalke, H. (2005). Botulinum toxin type B de novo therapy of cervical dystonia frequency of antibody induced therapy failure. J Neurol 252, 904-907.
18. Göchel, H., Wohlfarth, K., Frevert, J., Dengler, R. & Bigalke, H. (1997). Botulinum A toxin therapy: neutralizing and nonneutralizing Abs - therapeutic consequences. Exp Neurol 147, 96-102.
19. Inagi, K., Ford, C. N., Rodriquez, A. A., Schultz, E., Bless, D. M. & Heisey, D. M. (1997). Efficacy of repeated botulinum toxin injections as a function of timing. Ann Otol Rhinol Laryngol 106, 1012-1019.
20. Jankovic, J. (2002). Botulinum toxin clinical implications of antigenicity and immunoresistance. In Scientific and Therapeutic Aspects of Botulinum Toxin, pp. 409-415. Edited by M. F. Brin, M. Hallett & J. Jankovic. Philadelphia: Lippincott Williams & Wilkins.
21. Jankovic, J. (2004). Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatr 75, 951-957.
22. Jankovic, J., Hunter, C., Atassi, M. Z., Dolimbek, B. Z., Dolimbek, G. S. & BOS Research Group (2005). Botulinum toxin type B observational study (BOS). Mov Disord 20, S31.
23. Jemmerson, R. & Margoliash, E. (1978). In Immunobiology of Proteins and Peptides, vol. 1, pp. 119-129, Edited by M. Z. Atassi & A. B. Stavitsky. New York: Plenum.
24. Jemmerson, R. & Margoliash, E. (1979). Topographic antigenic determinants on cytochrome c. Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome. J Biol Chem 254, 12706-12716.
25. 2 and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants. J Am Chem Soc 127, 15933-15942.
26. Lee, J.-C., Yokota, K., Arimitsu, H. & 7 other authors (2005). Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 151, 3739-3747.
27. Lin, H. C., Chen, P. C., Cheng, T. J. & Chen, R. L. (2004). Formation of tannin-albumin nano-particles at neutral pH as measured by light scattering techniques. Anal Biochem 325, 117-120.
28. Marini, I., Moschini, R., Corso, A. D. & Mura, U. (2005). Chaperone-like features of bovine serum albumin: a comparison with alpha-crystallin. Cell Mol Life Sci 62, 3092-3099.
29. Means, G. E. & Feeney, R. E. (1971). Chemical Modification of Proteins. San Francisco: Holden-Day.
30. Militello, V., Casarino, C., Emanuele, A., Giostra, A., Pullara, F. & Leone, M. (2004). Aggregation kinetics of bovine serum albumin studied by FTIR spectroscopy and light scattering. Biophys Chem 107, 175-187.
31. Oliva, A., Santovena, A., Farina, J. & Llabres, M. (2003). Effect of high shear rate on stability of proteins: kinetic study. J Pharm Biomed Anal 33, 145-155.
32. Poewe, W., Deuschl, G., Nebe, A. & 8 other authors (1998). What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatr 64, 13-17.
33. Reichlin, M., Nisonoff, A. & Margoliash, E. (1970). Immunological activity of cytochrome c. 3. Enhancement of antibody detection and immune response initiation by cytochrome c polymers. J Biol Chem 245, 947-954.
34. Rosenberg, J. S., Middlebrook, J. L. & Atassi, M. Z. (1997). Localization of the regions on the C-terminal domain of the heavy chain of botulinum toxin A recognized by T-lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest 26, 491-504.
35. Rozak, D. A., Orban, J. & Bryan, P. N. (2005). G148-GA3: a streptococcal virulence module with atypical thermodynamics of folding optimally binds human serum albumin at physiological temperatures. Biochim Biophys Acta 1753, 226-233.
36. Vaiana, S. M., Emanuele, A., Palma-Vittorelli, M. B. & Palma, M. U. (2004). Irreversible formation of intermediate BSA oligomers requires and induces conformational changes. Proteins 55, 1053-1062.
37. Yablon, S. A., Daggett, S. & Brin, M. F. (2005). Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment. In 57th Annual Meeting of the American Academy of Neurology, Abstract P01.153, 12 April 2005, Miami Beach, Florida.
38. Young, C. R. & Atassi, M. Z. (1982). Genetic control of the immune response to myoglobin. IX. Overcoming genetic control of antibody response to antigenic sites by increasing the dose of antigen used in immunization. Immunogen 9, 343-351.